Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Econ #s
News

October Payrolls Revised To +546K; Sept. Revised To +379K

-Reuters

byBenzinga Newsdesk

December 3, 2021

1 minute read

-Reuters

Sanofi In-Licenses Preclinical Genetic Disease Candidate From An Unknown Biotech

By Vandana Singh

Today, 8:33 PM

French pharma major Sanofi SA (NASDAQ:SNY) entered into a collaboration and licensing agreement with little-known U.S. biotech miRecule, an innovator of next-generation…

SNY

Deutsche Bank Upgrades United Parcel Service to Buy, Raises Price Target to $220

By Benzinga Newsdesk

Today, 8:33 PM

Deutsche Bank analyst Amit Mehrotra upgrades United Parcel Service (NYSE:UPS) from Hold to Buy and raises the price target from $197 to $220.

UPS

Tempest Therapeutics Q3 EPS $(1.21) Up From $(11.22) YoY

By Benzinga Newsdesk

Today, 8:33 PM

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(1.21) per share. This is a 89.22 percent increase over losses of $(11.22) per share from the same period last year.

TPST

Luminar Technologies Q2 Adj. EPS $(0.18) Misses $(0.16) Estimate, Sales $9.90M Beat $8.59M Estimate

By Bill Haddad

Today, 8:33 PM

Luminar Technologies (NASDAQ:LAZR) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 125 percent decrease over losses of $(0.08) per share

LAZR

October Payrolls Revised To +546K; Sept. Revised To +379K

Related Posts

Sanofi In-Licenses Preclinical Genetic Disease Candidate From An Unknown Biotech

Deutsche Bank Upgrades United Parcel Service to Buy, Raises Price Target to $220

Tempest Therapeutics Q3 EPS $(1.21) Up From $(11.22) YoY

Luminar Technologies Q2 Adj. EPS $(0.18) Misses $(0.16) Estimate, Sales $9.90M Beat $8.59M Estimate